Division of Pulmonary and Sleep Medicine, Bethesda North Hospital, Cincinnati, OH, United States; Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States; Division of Cardiology, Ohio State University, Columbus, OH, United States.
Division of Cardiovascular Disease, University of Oklahoma College of Medicine, Oklahoma City, OK, United States.
Handb Clin Neurol. 2022;189:295-307. doi: 10.1016/B978-0-323-91532-8.00009-4.
Sleep disorders are prevalent in heart failure and include insomnia, poor sleep architecture, periodic limb movements and periodic breathing, and encompass both obstructive (OSA) and central sleep apnea (CSA). Polysomnographic studies show excess light sleep and poor sleep efficiency particularly in those with heart failure. Multiple studies of consecutive patients with heart failure show that about 50% of patients suffer from either OSA or CSA. While asleep, acute pathological consequences of apneas and hypopneas include altered blood gases, sleep fragmentation, and large negative swings in intrathoracic pressure. These pathological consequences are qualitatively similar in both types of sleep apnea, though worse in OSA than CSA. Sleep apnea results in oxidative stress, inflammation, and endothelial dysfunction, best documented in OSA. Multiple studies show that both OSA and CSA are associated with excess hospital readmissions and premature mortality. However, no randomized controlled trial (RCT) has been reported for OSA, but sensitivity analysis of two randomized controlled trials has concluded that use of positive airway pressure devices is associated with excess mortality in patients with heart failure and CSA. Phrenic nerve stimulation has shown improvement in sleep apnea events and daytime sleepiness; however, no randomized controlled trials have demonstrated improvement in survival in patients with heart failure. The correct identification and treatment of heart failure patients with sleep and breathing disorders could affect the long-term outcomes of these patients.
睡眠障碍在心力衰竭中很常见,包括失眠、睡眠结构不佳、周期性肢体运动和周期性呼吸,涵盖阻塞性(OSA)和中枢性睡眠呼吸暂停(CSA)。多导睡眠图研究显示,心力衰竭患者的浅睡眠和睡眠效率较差,尤其是那些有心力衰竭的患者。多项连续心力衰竭患者的研究表明,约 50%的患者患有 OSA 或 CSA。在睡眠过程中,呼吸暂停和低通气的急性病理后果包括血气改变、睡眠片段化和胸腔内压力的大幅负向波动。这两种类型的睡眠呼吸暂停在病理后果上是相似的,但 OSA 比 CSA 更严重。睡眠呼吸暂停导致氧化应激、炎症和内皮功能障碍,在 OSA 中得到了最好的证明。多项研究表明,OSA 和 CSA 都与住院次数增加和过早死亡有关。然而,目前尚未有关于 OSA 的随机对照试验(RCT)报道,但两项随机对照试验的敏感性分析得出结论,使用气道正压设备与心力衰竭和 CSA 患者的死亡率增加有关。膈神经刺激已显示出改善睡眠呼吸暂停事件和白天嗜睡;然而,没有随机对照试验证明心力衰竭患者的生存得到改善。正确识别和治疗心力衰竭合并睡眠和呼吸障碍的患者可能会影响这些患者的长期预后。